| 摘要 |
medicine, endocrinology. SUBSTANCE: decrease of activity of dipeptidase (DP IV) or enzyme DP IV with similar activity in mammalian blood is performed by prescription of effectors in causal sequence, endogenous (or additionally prescribed exogenous agents) insulinotropic peptides-stomach inhibitors polypeptides 1-42 (GIP1-42) and glucagons-liked peptide amides - I 7-36 (GLP-I7-36) (GLP-I7-37 and their analogues) that are cleaved with DP IV and DP IV similar enzymes in less degree that results to decrease and drop delaying the concentration of peptide hormones or their analogues. As a result of the enhanced stability attained by effect of DP IV the effectiveness of autogenous insulin is alternated that in turn results to the stimulation of body carbohydrate metabolism to be treated. Also, this results to decrease of blood glucose level to serum glucose content typical for hypoglycemia in the body to be treated. Invention provides to prevent or attenuate the metabolism disorders, for example, glucosuria, hyperlipidemia and possible severe metabolic acidosis, diabetes mellitus that are results of continuous enhanced blood glucose concentrations. Invention can be used for decrease of blood glucose level. EFFECT: enhanced effectiveness of effectors. 4 cl, 3 dwg, 3 ex |
